The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
India produces 60% of the world’s vaccine
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
The vaccine was 85 percent effective in preventing severe disease across all regions.
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
The company showcased three core programs developed through this platform
Subscribe To Our Newsletter & Stay Updated
